Home  /  Resource Library  /  Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton’s Tyrosine Kinase

Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton’s Tyrosine Kinase

Interim results of a phase II trials examing zanubrutinib for treatment of relapsed mantle cell lymphoma.